Fullife Healthcare is the leading parent company of the well-known wellness brands Fast&Up and Chicnutrix. Fullife Healthcare has raised ₹300 crore (approximately $32 million) in a Series D funding round. Elev8 Venture Partners led this capital infusion.
It is a significant move by the investment firm because this is their first venture into the direct-to-consumer (D2C) market segment. Its limited partners were also active participants of the round. It is an indication of high investor confidence in the business model of Fullife Healthcare and its future growth prospects.
Capital allocation and diversified portfolio
The new capital raised in this Series D round is to be used for several strategic projects, which will help the company grow faster across its varied branded portfolio. One of the main areas that Fullife Healthcare is looking at in the future is the exploration and expansion of newer health segments.
The firm will use this fund to position itself as a market leader in market segments like digestive health, sleep aid, and protein nutrition. Fullife Healthcare intends to satisfy a wider range of consumer wellness needs and target a stronger portion of the health supplementation market through product diversification.
Besides diversification in its products, the investment would be directed towards improved operational infrastructure in the company. Fullife Healthcare will increase its manufacturing capacity and invest heavily in innovations.
This involves the creation of new forms of products that aim at enhancing consumer experience. Fullife Healthcare possesses a strong brand portfolio, and its primary growth engines are Fast&Up and Chicnutrix. Fast&Up is prominently placed in the field of active nutrition, where it provides a broad selection of products such as protein supplements, work supplements, and supplements to boost immunity.
Launched in 2019, Chicnutrix is wellness-specifically tailored to women. The product line targets specialized segments such as skincare and haircare, and cures like PCOS care and UTI care. These two brands, and the NightOut label, add to the total portfolio of more than 100 stock-keeping units (SKUs) in the metabolic health, hydration, and beauty wellness category.
The sales of these variety of product lines were the sole revenue driving factor of the company in the previous fiscal year. Fullife Healthcare has a huge global presence as its products are sold in over 40 countries.
The company is not resting on its international laurels. Under the new funding, Fullife is also seeking to intensify its global distribution and expand its brand in emerging markets with high potential, particularly the United Kingdom, the United States, and the GCC region.
Omnichannel approach and financial performance
Although international growth is an ultimate priority, Fullife Healthcare is also keen on establishing its presence in the Indian market. The company is seeking to consider further market penetration through better consumer access through online and digital channels.
This omnichannel strategy entails expanding its distribution channels and drastically increasing its physical stores within the nation. The company will reduce the distance between digital and physical access and expects to provide its health and wellness products to more consumers in the Indian demographic.
The Elev8 Venture Partners investment should supply the tailwinds needed for these domestic endeavors. The trend of consumers to purchase wellness products in India is ever-growing, and Fullife Healthcare’s strategy to expand its presence by both retailing and digitalizing would be in line with the current consumer purchasing trends. Managing a vast range of SKUs and ensuring quality in various health categories has been one of the primary elements of the market mix at the company.
The recent round of funding has raised a total of $72 million to date by Fullife Healthcare. This involves a prior investment of $22 million raised from Morgan Stanley in 2021. Its financial report shows that the company has a positive improvement trend and an increasing efficiency in its operations. In the 2025 financial year (FY25), Fullife Healthcare records impressive growth of 36.4% year on year growth in operating revenue of ₹52.64 crore compared to ₹187.64 crore in the previous fiscal year (FY24).
The company has been able to reduce its financial loss even as it scaled its operations. In FY25, Fullife Healthcare made losses of ₹13.42 crore as compared with ₹30.16 crore in the preceding fiscal year. The bottom line result is an indicator that the company is headed towards a more sustainable and profitable business model despite its ongoing heavy investment in expansion and innovation.
Conclusion
The recent ₹300 crore investment round by Fullife Healthcare will be a turning point in its journey to be a leader in the wellness and nutrition industry worldwide. The company has the support of Elev8 Venture Partners and a well-defined roadmap on how to grow into new segments of the health industry, such as sleep support and digestive health, which positions it well for its next stage of growth.
A combination of robust international growth strategies and an intensive concentration on local stores and production facilities will allow Fullife to improve its brand image throughout the world, at the same time offering innovative health solutions to its increasing consumer clientele.
Read the full article here